This study is testing a new drug called IMVT-1402 for adults with Graves' disease (an autoimmune disorder that causes an overactive thyroid) who are still experiencing symptoms despite taking their current antithyroid medication. Researchers want to see if IMVT-1402 is effective, safe, and well-tolerated. You might be able to join if you are between 18 and 75 years old and have Graves' disease that isn't fully controlled by your current medication. The study will compare two different doses of IMVT-1402 to a placebo (an inactive substance) over 26 weeks. Success in this study means participants become euthyroid (have normal thyroid hormone levels) and can stop their antithyroid medication by Week 26. The current recruitment status is unclear.

Study design

This is a Phase 2b, multi-center, global study that will randomly assign about 210 participants to receive either IMVT-1402 or a placebo. It is a double-blind study, meaning neither you nor your doctor will know which treatment you are receiving.

What's involved

You would receive either IMVT-1402 or a placebo for 26 weeks. Other specific procedures are not detailed here.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at Week 26, which suggests follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.